Regulators OK Agilent buy of Stratagene
News May 14, 2007
Federal antitrust regulators said Thursday (10 may) they approved Agilent Technologies Inc.'s $246.2 million purchase of Stratagene Corp., which makes life science research and testing products.
According to a Federal Trade Commission notice, the government has completed its investigation of the deal and ended a waiting period on the cash transaction.
Santa Clara, Calif.-based Agilent, which makes measurement and testing devices for the electronics, communications, and life sciences industries, said April 6 that it would buy the La Jolla, Calif.-based Stratagene.
Shares of Agilent dropped 66 cents to $36.78 in morning trading Thursday, while shares of Stratagene rose 8 cents to $10.85.
Old age is the greatest risk factor for many diseases, including Alzheimer's disease (AD) and cancer. Geroprotectors are a recently identified class of anti-aging compounds. New research has now identified a unique subclass of these compounds, dubbed geroneuroprotectors (GNPs), which are AD drug candidates and slow the aging process in mice.READ MORE